Eli Lilly shares rose 6.6% following an earnings release that beat analyst expectations across both top and bottom lines, driven by continued surging demand for its flagship incretin therapies. Third-quarter revenue jumped 38.6% year-over-year to $24.4 billion, outpacing the analyst consensus of $22.62 billion, while non-GAAP earnings per share reached $7.48 against an expected $6.61. Sales of diabetes and obesity treatments Mounjaro and Zepbound powered the outperformance, prompting management to raise full-year revenue guidance to between $91 billion and $92 billion. Executive commentary framed the moment as "the middle of the largest new category expansion in the history of the pharmaceutical industry," reassuring investors that underlying patient uptake remains durable enough to absorb ongoing price reductions across key markets.

Questions and answers
What did Eli Lilly and Company report for Q3 2026?
Revenue: $24.4B; Operating income: $8.61B; Net income: $6.45B.
How did Eli Lilly and Company shares react?
Up 6.6%: from the close on Oct 28, 2026 (before call day) to the close on Oct 29, 2026. That is #6 of 23 companies this season.
What is in the full report?
Takeaways from the whole brief, Management commentary, Guidance quality, Capital allocation, Accounting quality, Quarter-to-quarter continuity, Earnings scorecard, Analyst Q&A, Management tone.